The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity

Trends in Immunology

Volumn 22, Issue 5, 2001, Pages 269-276

  Wang, Rong Fu ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; HYBRID PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; GENE EXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MELANOMA; NONHUMAN; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MODELS, IMMUNOLOGICAL;

EID: 0034919646     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(01)01896-8     Document Type: Review

References (78)

1. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report
2. Tumor antigens recognized by T lymphocytes
3. A new era for cancer immunotherapy based on the genes that encode cancer antigens
4. Human tumor antigens for cancer vaccine development
5. Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
8. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
9. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection
10. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
11. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
12. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
13. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
14. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
15. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
16. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
17. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
18. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma
19. A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum
20. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
21. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
22. The dendritic cell and human cancer vaccines
23. Prognostic significance of hypopigmentation in malignant melanoma
24. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
25. Vitiligo in patients with melanoma: Normal tissue antigens can be targeted for cancer immunotherapy
26. Implicating a role for immune recognition of self in tumor rejection: Passive immunization against the Brown locus protein
27. + T lymphocytes
28. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
29. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo
30. + T cells and their role in antitumor immune responses
31. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
32. + T cell responses in antitumor immunity
33. + T-cell subsets in autoimmunity
34. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
35. + T cells
36. Crossregulation between Th1 and Th2 cells
37. + T cells in the antitumor immune response
38. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
39. Help for cytotoxic-T-cell responses is mediated by CD40 signaling
40. + T-helper and a T-killer cell
41. Dendritic cells and the control of immunity
42. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
43. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
44. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
45. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells
46. Immunotherapy for cancer
47. Clinical trials of antibody therapy
48. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3
49. A unique tumor antigen produced by a single amino acid substitution
50. + T cells
51. MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation
52. Invariant chain structure and MHC class II function
53. Expression of endogeous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins
54. Efficient loading of HLA-DR with a T helper epitope by genetic exchange of CLIP
55. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells
56. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
57. + T cells
58. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
59. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules
60. Identification of HLA-class-II-restricted epitopes of autoantigens in transgenic mice
61. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
62. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase
63. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient
64. + T cells
65. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells
66. + T lymphocytes
67. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
68. + T cells
69. + T lymphocytes of patients with NY-ESO-1-expressing melanoma
70. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
71. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA-DP4 allele: Association with NY-ESO-1 antibody production
72. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
73. DNA vaccines
74. Cancer therapy using a self-replicating RNA vaccine
75. The makings of a tumor rejection antigen
76. + T cell- and IL-2-dependent mechanism
77. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
78. Costimulatory wars: The tumor menace